

Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis

SUPPLEMENTARY

Supplementary file

1. Pharmacological and non-pharmacological therapeutic strategies for difficult-to-treat RA patients

1a. Therapeutic strategies in patients with limited DMARD options

Clinical question

- What are the management options when drug choices are limited to treat persistent inflammation in D2T RA?
- What are the management options for patients with comorbidities?

Epidemiological question

What are effective management options when DMARD choices are limited, because of adverse events, comorbidity or contraindications, to treat persistent inflammation in D2T RA?

- P: D2T RA patients with inflammatory activity and limited DMARD options
- I: Management options (including non-pharmacological therapy)
- C: No or different management options
- O: Efficacy and/or safety/tolerability

1b. Therapeutic strategies in patients who failed ≥ 1 b/tsDMARD

Clinical question

What are the management options for refractory RA?

Epidemiological question

What are effective management options for true refractory RA?

- P: D2T RA with inflammation not explained by other causes (true refractory RA)

- I: Management options (including non-pharmacological therapy)
- C: No or different management options
- O: Reduction of RA inflammation

1c. Therapeutic strategies in patients with predominantly non-inflammatory complaints

Clinical question

- What are the management options for D2TRA patients that primarily have non-inflammatory complaints (e.g. fatigue, pain, reduced quality of life and physical functioning)?

Epidemiological question

What are effective management options for RA patients with persistent complaints that are not explained by active inflammation?

- P: D2T RA patients with persistent complaints not explained by active inflammation
- I: Management options (including non-pharmacological therapy)
- C: No or different management options
- O: Reduction in (specific) complaints

Search in short

Rheumatoid arthritis AND Terms for difficult-to-treat RA, terms for fatigue, and terms for adverse events, and comorbidities that may limit DMARD choices AND General terms for treatment, and specific DMARDs, GCs, NSAIDs, non-pharmacological treatment options AND General terms for efficacy and tolerability, and often used outcome measures AND Adjusted Pubmed therapeutic query (to focus more generally on comparative studies not only RCTs)

Search in full

PubMed: (RA[Title/Abstract] OR Rheumatoid arthritis[Title/Abstract] OR "arthritis, rheumatoid"[MeSH]) AND (Established[Title/Abstract] OR Previously treated[Title/Abstract] OR Failed[Title/Abstract] OR Failure[Title/Abstract] OR Refractoriness[Title/Abstract] OR Refractory[Title/Abstract] OR Difficult to treat[Title/Abstract] OR Irresponsive[Title/Abstract] OR Irresponsiveness[Title/Abstract] OR Resistant[Title/Abstract] OR Resistance[Title/Abstract] OR Unsuccessful[Title/Abstract] OR Comorbidity[Title/Abstract] OR Comorbidity[Mesh] OR Comorbidities[Title/Abstract] OR Co-morbidity[Title/Abstract] OR Co-morbidities[Title/Abstract] OR Multi-morbidity[Title/Abstract] OR Multi-morbidities[Title/Abstract] OR Multimorbidity[Title/Abstract] OR Multimorbidity[MeSH] OR Multimorbidities[Title/Abstract] OR Contraindicated[Title/Abstract] OR Contraindication[Title/Abstract] OR Contra-indication[Title/Abstract] OR Contra-indicated[Title/Abstract] OR Complication[Title/Abstract] OR Complications[Title/Abstract] OR Adverse event[Title/Abstract] OR Adverse events[Title/Abstract] OR Adverse reaction[Title/Abstract] OR Adverse reactions[Title/Abstract] OR Adverse effect[Title/Abstract] OR Adverse effects[Title/Abstract] OR Side effect[Title/Abstract] OR Side effects[Title/Abstract] OR Adverse drug reaction[Title/Abstract] OR Adverse drug reactions[Title/Abstract] OR (Drug-Related Side Effects and Adverse Reactions [Mesh]) OR

Infection[Title/Abstract] OR Infections[Title/Abstract] OR Infection[MeSH] OR Hepatitis[Title/Abstract] OR Hepatitis[MeSH] OR HIV[Title/Abstract] OR Human Immunodeficiency Virus[Title/Abstract] OR HIV[Mesh] OR Tuberculosis[Mesh] OR TBC[Title/Abstract] OR Latent tuberculosis[Mesh] OR Malignancy[Title/Abstract] OR Malignancies[Title/Abstract] OR Neoplasms[MeSH] OR Tumor[Title/Abstract] OR Tumors[Title/Abstract] OR Cancer[Title/Abstract] OR Lung disease[Title/Abstract] OR Lung diseases[Title/Abstract] OR Lung diseases[MeSH] OR Asthma[Title/Abstract] OR Asthma[MeSH] OR COPD[Title/Abstract] OR Pulmonary Disease, Chronic Obstructive[MeSH] OR Chronic obstructive pulmonary disease[Title/Abstract] OR Chronic bronchitis[Title/Abstract] OR Bronchitis, chronic[Title/Abstract] OR Pulmonary fibrosis[Title/Abstract] OR Pulmonary fibrosis[MeSH] OR interstitial lung disease[Title/Abstract] OR Interstitial lung diseases[Title/Abstract] OR Lung diseases, interstitial[MeSH] OR Cardiovascular disease[Title/Abstract] OR CV disease[Title/Abstract] OR CVD[Title/Abstract] OR Cardiovascular disease[MeSH] OR Hypertension[Title/Abstract] OR Hypertension[MeSH] OR High blood pressure[Title/Abstract] OR Hyperlipidemia[Title/Abstract] OR Hyperlipidaemia[Title/Abstract] OR Hyperlipidemias[MeSH] OR Cardiac failure[Title/Abstract] OR Cardiomyopathy[Title/Abstract] OR Cardiomyopathies[MeSH] OR Kidney disease[Title/Abstract] OR Kidney diseases[Title/Abstract] OR Kidney diseases[MeSH] OR Renal disease[Title/Abstract] OR Renal diseases[Title/Abstract] OR Kidney failure[Title/Abstract] OR Kidney failures[Title/Abstract] OR Renal failure[Title/Abstract] OR Renal failures[Title/Abstract] OR Renal dysfunction[Title/Abstract] OR Renal dysfunctions[Title/Abstract] OR Kidney dysfunction[Title/Abstract] OR Kidney dysfunctions[Title/Abstract] OR Renal insufficiency[Title/Abstract] OR Kidney insufficiency[Title/Abstract] OR Liver disease[Mesh] OR Liver failure[Title/Abstract] OR Liver dysfunction[Title/Abstract] OR Liver dysfunctions[Title/Abstract] OR Liver insufficiency[Title/Abstract] OR Liver disease[Title/Abstract] OR Liver diseases[Title/Abstract] OR Liver cirrhosis[Title/Abstract] OR Liver enzyme elevation[Title/Abstract] OR ALAT[Title/Abstract] OR ALT[Title/Abstract] OR Aspartate transaminase[Title/Abstract] OR Aspartate aminotransferase[Title/Abstract] OR Aspartate aminotransferases[Mesh] OR serum glutamic oxaloacetic transaminase[Title/Abstract] OR SGOT[Title/Abstract] OR ASAT[Title/Abstract] OR AST[Title/Abstract] OR Alanine transaminase[Title/Abstract] OR "Alanine Transaminase"[Mesh] OR Osteoporosis[Title/Abstract] OR Osteoporosis[MeSH] OR Osteoporosis, Postmenopausal[MeSH] OR Osteopenia[Title/Abstract] OR Diabetes mellitus[Title/Abstract] OR Diabetes mellitus[MeSH] OR DM[Title/Abstract] OR Pregnancy[Title/Abstract] OR Pregnancy[MeSH] OR Ulcus ventriculi[Title/Abstract] OR Ulcus duodeni[Title/Abstract] OR Stomach ulcer[MeSH] OR Fatigue[Title/Abstract] OR Fatigue[MeSH] OR Fatigue Syndrome, Chronic[Title/Abstract] OR Fatigue Syndrome, Chronic[MeSH] OR Thrombosis[Title/Abstract] OR Thrombosis[MeSH] OR Thrombophilia[Title/Abstract] OR Thrombophilia[MeSH]) **AND** (Switching[Title/Abstract] OR DMARD[Title/Abstract] OR DMARDs[Title/Abstract] OR "disease modifying antirheumatic drug"[Title/Abstract] OR "disease modifying antirheumatic drugs"[Title/Abstract] OR "disease modifying anti-rheumatic drug"[Title/Abstract] OR "disease modifying anti-rheumatic drugs"[Title/Abstract] OR "Antirheumatic Agents"[Mesh] OR Glucocorticoids[Title/Abstract] OR "glucocorticoids"[MeSH Terms] OR corticosteroid[Title/Abstract] OR corticosteroids[Title/Abstract] OR NSAID[Title/Abstract] OR NSAIDs[Title/Abstract] OR "anti-inflammatory agents, non-steroidal"[MeSH Terms] OR Non-

Steroidal Anti-Inflammatory Agents[Title/Abstract] OR Non Steroidal Anti Inflammatory Agents[Title/Abstract] OR Nonsteroidal Anti-Inflammatory Agents[Title/Abstract] OR Nonsteroidal Anti Inflammatory agents[Title/Abstract] OR Nonsteroidal Antiinflammatory Agents[Title/Abstract] OR Antiinflammatory Agents, Non Steroidal[Title/Abstract] OR Anti Inflammatory Agents, Nonsteroidal[Title/Abstract] OR Antiinflammatory Agents, Nonsteroidal[Title/Abstract] OR Anti-Inflammatory Analgetics[Title/Abstract] OR Analgetics, Anti-Inflammatory[Title/Abstract] OR "cyclooxygenase inhibitors"[MeSH Terms] OR "cyclooxygenase 2 inhibitors"[MeSH Terms] OR Physical therapy[Title/Abstract] OR Physiotherapy[Title/Abstract] OR Cognitive behavioral therapy[Title/Abstract] OR "Balneology/therapeutic use"[Mesh] OR "Balneology/therapy"[Mesh] OR Balneotherapy[Title/Abstract] OR Non-pharmacological[Title/Abstract] OR "Massage/therapy"[Mesh] OR "Massage/therapeutic use"[Mesh] OR Reflexology[Title/Abstract] OR "Complementary therapies"[Mesh] OR Methotrexate[tiab] OR MTX[tiab] OR "Methotrexate"[Mesh] OR Leflunomide[tiab] OR "leflunomide"[Supplementary Concept] OR Sulfasalazine[tiab] OR "Sulfasalazine"[Mesh] OR Salazosulfapyridine[tiab] OR Hydroxychloroquine[tiab] OR Chloroquine[tiab] OR "Chloroquine"[Mesh] OR Isoxazole[tiab] OR "Isoxazoles"[Mesh] OR Gold[tiab] OR "Gold"[Mesh] OR "Gold compounds"[Mesh] OR Azathioprine[tiab] OR "Azathioprine"[Mesh] OR Cyclosporine[tiab] OR "Cyclosporine"[Mesh] OR Penicillamine[tiab] OR "Penicillamine"[Mesh] OR Cyclophosphamide[tiab] OR "Cyclophosphamide"[Mesh] OR "Mycophenolic acid"[tiab] OR "Mycophenolic acid"[Mesh] OR Pyrroles[tiab] OR "Pyrroles"[Mesh] OR Chlorambucil[tiab] OR "Chlorambucil"[Mesh] OR Mycophenolate[tiab] OR "Mycophenolic acid"[Mesh] OR Minocycline[tiab] OR "Minocycline"[Mesh] OR Tofacitinib[tiab] OR "tofacitinib"[Supplementary Concept] OR Baricitinib[tiab] OR "baricitinib"[Supplementary Concept] OR Filgotinib[tiab] OR "GLPG0634"[Supplementary Concept] OR Peficitinib[tiab] OR "peficitinib"[Supplementary Concept] OR Decernotinib[tiab] OR "2-((2-(1H-pyrrolo(2,3-b)pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide"[Supplementary Concept] OR Ruxolitinib[tiab] OR "INCB018424"[Supplementary Concept] OR Upadacitinib[tiab] OR "Biological Products"[Mesh] OR Infliximab[tiab] OR "Infliximab"[Mesh] OR Golimumab[tiab] OR Adalimumab[tiab] OR "Adalimumab"[Mesh] OR Certolizumab[tiab] OR "Certolizumab Pegol"[Mesh] OR Etanercept[tiab] OR "Etanercept"[Mesh] OR Abatacept[tiab] OR "Abatacept"[Mesh] OR Tocilizumab[tiab] OR "tocilizumab"[Supplementary Concept] OR Anakinra[tiab] OR "Interleukin 1 Receptor Antagonist Protein"[Mesh] OR Rituximab[tiab] OR "Rituximab"[Mesh] OR Secukinumab[tiab] OR Secukinumab[Supplementary Concept] OR Dexamethasone[Title/Abstract] OR "dexamethasone"[MeSH Terms] OR Betamethasone[Title/Abstract] OR "betamethasone"[MeSH Terms] OR Methylprednisolone[Title/Abstract] OR "methylprednisolone"[MeSH Terms] OR Prednisolone[Title/Abstract] OR "prednisolone"[MeSH Terms] OR Prednisone[Title/Abstract] OR "prednisone"[MeSH Terms] OR Triamcinolone[Title/Abstract] OR "triamcinolone"[MeSH Terms] OR Triamcinolone acetonide[Title/Abstract] OR "triamcinolone acetonide"[MeSH Terms] OR Celecoxib[Title/Abstract] OR "celecoxib"[MeSH Terms] OR Diclofenac[Title/Abstract] OR "diclofenac"[MeSH Terms] OR Etodolac[Title/Abstract] OR "etodolac"[MeSH Terms] OR etoricoxib[Title/Abstract] OR Ibuprofen[Title/Abstract] OR "ibuprofen"[MeSH Terms] OR Ketoprofen[Title/Abstract] OR "ketoprofen"[MeSH Terms] OR Meclofenamic Acid[Title/Abstract] OR "meclofenamic acid"[MeSH Terms] OR meloxicam[Title/Abstract] OR

Naproxen[Title/Abstract] OR "naproxen"[MeSH Terms] OR Niflumic Acid[Title/Abstract] OR "niflumic acid"[MeSH Terms] OR Piroxicam[Title/Abstract] OR "piroxicam"[MeSH Terms] OR Plasmapheresis[Title/Abstract] OR Plasmapheresis[MeSH] OR Intravenous immunoglobulin[Title/Abstract] OR Immunoglobulins, Intravenous[MeSH] OR Intravenous immunoglobulins[Title/Abstract] OR Intravenous Antibodies[Title/Abstract] OR IVIG[Title/Abstract] OR Ustekinumab[Title/Abstract] OR Ustekinumab[MeSH] OR brodalumab[Title/Abstract] OR brodalumab[Supplementary Concept] OR Pain management[MeSH] OR Pain management[Title/Abstract] **AND** (Disease activity[Title/Abstract] OR remission[Title/Abstract] OR Drug survival[Title/Abstract] OR Persistence[Title/Abstract] OR Therapeutic success[Title/Abstract] OR Response[Title/Abstract] OR Effectiveness[Title/Abstract] OR Efficacy[Title/Abstract] OR Effective[Title/Abstract] OR Toxic*[Title/Abstract] OR Safety[Title/Abstract] OR Tolerability[Title/Abstract] OR Tolerable[Title/Abstract] OR Adverse event[Title/Abstract] OR Adverse events[Title/Abstract] OR Adverse effect[Title/Abstract] OR Adverse effects[Title/Abstract] OR Adverse reaction[Title/Abstract] OR Adverse reactions[Title/Abstract] OR Side-effect[Title/Abstract] OR Side-effects[Title/Abstract] OR Averse drug reaction[Title/Abstract] OR Adverse drug reactions[Title/Abstract] OR (Drug-Related Side Effects and Adverse Reactions [Mesh]) OR DAS28[Title/Abstract] OR DAS[Title/Abstract] OR DAS44[Title/Abstract] OR CDAI[Title/Abstract] OR SDAI[Title/Abstract] OR ACR20[Title/Abstract] OR ACR50[Title/Abstract] OR ACR70[Title/Abstract] OR ACR-20[Title/Abstract] OR ACR-50[Title/Abstract] OR ACR-70[Title/Abstract]) **AND** ("clinical studies as topic"[MeSH Terms] OR (clinical[Tiab] AND (trial[Tiab] OR trials[Tiab]))) OR (randomized[Tiab] AND (trial[Tiab] OR trials[Tiab]))) OR (randomised[Tiab] AND (trial[Tiab] OR trials[Tiab]))) OR "observational study"[Tiab] OR "non-interventional study"[Tiab] OR "observational studies"[Tiab] OR "non-interventional studies"[Tiab] OR "Clinical Study"[Publication Type] OR "Comparative study"[Publication Type] OR "Clinical Study"[Tiab] OR "Comparative study"[Tiab] OR "Clinical Studies"[Tiab] OR "Comparative studies"[Tiab])

Searches in Embase and Cochrane are available on request.

Exclusion criteria

- Duplicate
- Language other than English
- Animal study
- Wrong publication type (e.g., Editorial, case report or case series, abstract not of ACR or EULAR of past 2 years, narrative review)
- 1a:
 - o No or less than 10% (or n <10) RA patients with contraindications because of comorbidities or adverse events
 - o No results presented for this (sub)group
 - o No quantitative results on efficacy or safety
- 1b:
 - o No RA patients with true refractory disease
 - o Not failed ≥ 1 b/tsDMARD
 - o Failing ≥ 2 b/tsDMARD not allowed according to inclusion criteria

- No quantitative results on efficacy
- No comparison between different strategies (doesn't need to be formal testing)
- 1c:
 - No RA patients with non-inflammatory complaints (e.g. pain, fatigue, reduced function, reduced quality of life) that cannot be explained by active inflammation
 - Not failed ≥ 1 DMARD
 - No quantitative results on efficacy
 - No comparison between different strategies

Predetermined items for data extraction

- Study:
 - 1st Author
 - Title
 - Publication year
 - Publication type (original study/SLR/abstract)
 - Study design
 - General description of population
- Baseline characteristics:
 - Number of patients
 - Gender (female)
 - Age (years)
 - DAS28 (or another composite index)
 - RF positivity
 - ACPA positivity
 - Disease duration (days/months/years)
 - DMARD history
 - Current DMARD therapy
 - 1a: Contraindications (including comorbidities and previous adverse events, as detailed as possible)
 - 1c: Non-inflammatory complaints (as detailed as possible)
- Determinant:
 - Intervention:
 - Name/description
 - Number of patients
 - Dose
 - Administration route
 - Treatment strategy (step-up, treat-to-target, step-down, stable)
 - Duration of treatment (days/months/years)
 - Control:
 - Name/description
 - Number of patients
 - Dose

- Administration route
 - Treatment strategy (step-up, treat-to-target, step-down, stable)
 - Duration of treatment (days/months/years)
- Outcome:
 - Name/description of outcome
 - Number and percentage of responders (meeting the outcome) in intervention group
 - Number and percentage of responders (meeting the outcome) in control group
 - Association measure:
 - OR (95%CI, p-value)
 - Risk ratio (95%CI, p-value)
 - Risk difference (95%CI, p-value)
 - Hazard ratio (95%CI, p-value)
 - Mean outcome in intervention group (standard deviation)
 - Mean outcome in control group (standard deviation)
 - Mean difference (standard error, 95%CI)
 - Other
- Other remarks (e.g. funding, conflicts of interest, things that stand out)
- Additional items for SLRs:
 - Number of studies included in qualitative analysis
 - Number of studies included in quantitative analysis (meta-analysis)
 - Narrative summary of baseline characteristics
 - Narrative summary of results
 - Measure to assess risk of bias
 - Outcome of risk of bias (range)
 - Narrative summary of risk of bias
 - References of included studies

2. Identification and optimisation of suboptimal goal setting and suboptimal self-management

2a. Identification of a mismatch in goal setting between patient and health care professional

Clinical question

How to address a mismatch between management goals of patients and rheumatologists?

Epidemiological question

How to identify a mismatch between management goals of patients and health care professionals in difficult to treat RA patients?

- P: D2T RA patients where a mismatch between their management goals and the health care professional's management goals is suspected

- I: diagnostic/screening 'tests'/characteristics for mismatch of management goals
- C: Presence/level/absence of a mismatch of management goals according to a reference standard
- O: Diagnostic test value of the techniques to establish a mismatch of management goals

2b. Optimisation of a mismatch in goal setting between patient and health care professional

Clinical question

How to optimise the goal setting by the patient and rheumatologist?

Epidemiological question

How to optimise shared goal setting by the difficult to treat RA patient and health care professional?

- P: D2T RA patients with a mismatch between management goal of patient and health care professional
- I: Interventions to optimize goals setting by patient and health care professional
- C: No or another intervention
- O: Reduction of complaints

2c. Identification of suboptimal self-management

Clinical question

How to detect suboptimal self-management?

Epidemiological question

How to detect suboptimal self-management in difficult to treat RA patients?

- P: D2T RA patients who are suspected of suboptimal self-management
- I: diagnostic/screening 'tests'/characteristics for self-management
- C: Presence/level/absence of (adequate) self-management according to a reference standard
- O: Diagnostic test value of the techniques to establish (adequate) self-management

2d. Optimisation of suboptimal self-management

Clinical question

How to improve self-management to improve complaints?

Epidemiological question

How to improve self-management in difficult to treat RA patients to improve complaints?

- P: D2T RA patient with suboptimal self-management

- I: Interventions to improve self-management
- C: No or another intervention
- O: Reduction of complaints

Search in short

Rheumatoid arthritis AND Terms for management goals and self-management

Search in full

PubMed: (RA[Title/Abstract] OR Rheumatoid arthritis[Title/Abstract] OR "arthritis, rheumatoid"[MeSH Terms]) **AND** (Setting goal[Title/Abstract] OR Setting goals[Title/Abstract] OR Goal-setting[Title/Abstract] OR Goal-settings[Title/Abstract] OR Self care[Title/Abstract] OR Self cares[Title/Abstract] OR Self management[Title/Abstract] OR Management goal[Title/Abstract] OR Management goals[Title/Abstract] OR Treatment goal[Title/Abstract] OR Treatment goals[Title/Abstract] OR Self efficacy[Title/Abstract] OR Self efficacy[Mesh])
Searches in Embase and Cochrane are available on request.

Exclusion criteria

- Duplicate
- Language other than English
- Animal study
- Wrong publication type (e.g., Editorial, case report or case series, abstract not of ACR or EULAR of past 2 years, narrative review)
- No RA patients
- 2a:
 - o No diagnostic test for detection of a mismatch in goal setting between patient and health care professional (diagnostic test can also be screening test or patient characteristic; it can also be i.e. a rating of importance of 'goals' for patients/ doctors)
 - o No information on outcomes of diagnostic characteristic/test (at least a comparison of the importance/frequency of 'goals' between patients and health care providers needs to be given; qualitative outcomes, e.g. interviews, are also of interest)
- 2b:
 - o No interventions to optimise goal setting
 - o No comparison between different strategies (doesn't need to be formal testing: pre- vs post-intervention also of interest)
 - o No quantitative results on efficacy
- 2c:
 - o No diagnostic test for self-management (diagnostic test can also be screening test or patient characteristic; it can also be i.e. a rating of importance of 'self-management items/goals/domains' for patients/controls)

- No information on outcomes of diagnostic characteristic/test (at least a comparison of the 'self-management items/scores' with a control population (or "norm scores") should be given; qualitative outcomes, e.g. interviews, are also of interest)
- 2d:
 - No interventions to optimise self-management
 - No comparison between different strategies (doesn't need to be formal testing: pre- vs post-intervention also of interest)
 - No quantitative results on efficacy

Predetermined items for data extraction

- Study:
 - 1st Author
 - Title
 - Publication year
 - Publication type (original study/SLR/abstract)
 - Country where study was performed
 - Setting (general practitioner/secondary care/tertiary care)
 - Study design
 - General description of population
- Baseline characteristics:
 - Number of patients
 - Gender (female)
 - Age (years)
 - DAS28 (or another composite index)
 - RF positivity
 - ACPA positivity
 - Disease duration (days/months/years)
 - DMARD history
 - Current DMARD therapy
 - 2a/2b: Definition/description of mismatch in goal setting
 - 2c/2d: Definition/description of suboptimal self-management
- Determinant:
 - 2a/2c:
 - Diagnostic test:
 - Name/description
 - Cut-off (if applicable)
 - Reference standard:
 - Name/description
 - Cut-off (if applicable)
 - Time interval between diagnostic test and reference standard
 - 2b/2d:
 - Intervention:

- Name/description
 - Number of patients
 - Duration of treatment (days/months/years)
 - Control:
 - Name/description
 - Number of patients
 - Duration of treatment (days/months/years)
- Outcome:
 - 2a/2c:
 - Diagnostic test value to establish presence/level of mismatch in goal setting or suboptimal goal setting, respectively:
 - Diagnostic OR (95%CI, p-value)
 - AUC-ROC (95%CI, p-value)
 - PPV (95%CI)
 - NPV (95%CI)
 - Sensitivity (95%CI)
 - Specificity (95%CI)
 - LR+ (95%CI)
 - LR- (95%CI)
 - Correlation coefficient (95%CI, p-value)
 - Other
 - Comparison in frequency/importance of management goals or self-management items, respectively, between patients and health care professionals:
 - Description of comparison
 - Frequency in patients
 - Frequency in health care professionals
 - Calculable test value:
 - 2a:
 - Number of RA patients with mismatch in goal setting and with positive test
 - Number of RA patients with mismatch in goal setting and with negative test
 - Number of RA patients without mismatch in goal setting and with positive test
 - Number of RA patients without mismatch in goal setting and with negative test
 - 2c:
 - Number of RA patients with optimal self-management and with positive test
 - Number of RA patients with optimal self-management and with negative test

- Number of RA patients with suboptimal self-management with positive test
 - Number of RA patients with suboptimal self-management with negative test
 - 2b/2d:
 - Name/description of outcome
 - Number and percentage of responders (meeting the outcome) in intervention group
 - Number and percentage of responders (meeting the outcome) in control group
 - Association measure:
 - OR (95%CI, p-value)
 - Risk ratio (95%CI, p-value)
 - Risk difference (95%CI, p-value)
 - Hazard ratio (95%CI, p-value)
 - Mean outcome in intervention group (standard deviation)
 - Mean outcome in control group (standard deviation)
 - Mean difference (standard error, 95%CI)
 - Other
- Other remarks (e.g. funding, conflicts of interest, things that stand out)
- Additional items for SLRs:
 - Number of studies included in qualitative analysis
 - Number of studies included in quantitative analysis (meta-analysis)
 - Narrative summary of baseline characteristics
 - Narrative summary of results
 - Measure to assess risk of bias
 - Outcome of risk of bias (range)
 - Narrative summary of risk of bias
 - References of included studies